Novartis initiates long-term follow-up study for OAV101 in Spinal Muscular Atrophy
Novartis is conducting a long-term follow-up study to evaluate the safety and efficacy of OAV101 over five years.
Asset / Drug
Drug and asset intelligence for OAV101 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.